Jesús
San Miguel Izquierdo

2025

1. A plain language summary of the ICARIA study, comparing isatuximab–pomalidomide– dexamethasone with pomalidomide– dexamethasone in people with multiple myeloma

   Future Oncology, Vol. 21, Núm. 6, pp. 653-663

2. Bortezomib, melphalan, and prednisone with or without daratumumab in transplant-ineligible patients with newly diagnosed multiple myeloma (ALCYONE): final analysis of an open-label, randomised, multicentre, phase 3 trial

   The Lancet Oncology, Vol. 26, Núm. 5, pp. 596-608

3. Clinical significance of complete remission and measurable residual disease in relapsed/refractory multiple myeloma patients treated with T-cell redirecting immunotherapy

   American Journal of Hematology, Vol. 100, Núm. 1, pp. 93-102

4. Co-Occurrence of Cytogenetic Abnormalities and High-Risk Disease in Newly Diagnosed and Relapsed/Refractory Multiple Myeloma

   Journal of Clinical Oncology, Vol. 43, Núm. 24, pp. 2679-2691

5. Comparative Efficacy of Ciltacabtagene Autoleucel Versus Standard-of-Care Treatments for Patients with Previously Treated Relapsed or Refractory Multiple Myeloma: A Matching-Adjusted Indirect Comparison

   Advances in Therapy, Vol. 42, Núm. 7, pp. 3223-3239

6. Dynamics of Mutant Hematopoietic Progenitor Cells Are Not Associated with Clinical Outcomes in Multiple Myeloma

   BLOOD CANCER DISCOVERY, Vol. 6, Núm. 3, pp. 203-216

7. EHA–EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma

   Nature Reviews Clinical Oncology, Vol. 22, Núm. 9, pp. 680-700

8. European Myeloma Network Group review and consensus statement on primary plasma cell leukemia

   Annals of Oncology, Vol. 36, Núm. 4, pp. 361-374

9. High-risk features of early relapse in newly-diagnosed multiple myeloma: The impact of cytogenetics and response to initial therapy

   HemaSphere, Vol. 9, Núm. 4

10. Induction therapy with bortezomib, melphalan, and prednisone followed by lenalidomide and dexamethasone versus carfilzomib, lenalidomide, and dexamethasone with or without daratumumab in older, fit patients with newly diagnosed multiple myeloma (GEM-2017FIT): a phase 3, open-label, multicentre, randomised clinical trial

    The Lancet Haematology, Vol. 12, Núm. 8, pp. e588-e598

11. International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma

    Journal of Clinical Oncology, Vol. 43, Núm. 24, pp. 2739-2751

12. Is t(11;14) Always a Standard-Risk Cytogenetic Abnormality? Results From GEM05MENOS65 and GEM2012 PETHEMA/GEM Transplantation Trials

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 25, Núm. 7, pp. 494-504

13. Machine learning risk stratification strategy for multiple myeloma: Insights from the EMN–HARMONY Alliance platform

    HemaSphere, Vol. 9, Núm. 10

14. Minimal Residual Disease–Based End Point for Accelerated Assessment of Clinical Trials in Multiple Myeloma: A Pooled Analysis of Individual Patient Data From Multiple Randomized Trials

    Journal of Clinical Oncology, Vol. 43, Núm. 11, pp. 1289-1301

15. Minimally Invasive Assessment of Peripheral Residual Disease during Maintenance or Observation in Transplant-Eligible Patients with Multiple Myeloma

    Journal of Clinical Oncology, Vol. 43, Núm. 2, pp. 125-132

16. Myeloma: a sky full of MRD stars

    Blood

17. Opportunities and challenges for MRD assessment in the clinical management of multiple myeloma

    Nature Reviews Clinical Oncology, Vol. 22, Núm. 6, pp. 424-438

18. Optimising T-cell immunotherapy in patients with multiple myeloma: practical considerations from the European Myeloma Network

    The Lancet Haematology, Vol. 12, Núm. 8, pp. e635-e649

19. Recommendations for the study of monoclonal gammopathies in the clinical laboratory. A consensus of the Spanish society of laboratory medicine and the Spanish society of hematology and hemotherapy. Part III: clinical and analytical recommendations for the study of monoclonal gammopathies by MALDI-TOF mass spectrometry

    Clinical Chemistry and Laboratory Medicine

20. Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1–2 study

    The Lancet Haematology, Vol. 12, Núm. 4, pp. e269-e281